← Leaderboards
Zhenkun Lou
Mayo Clinic Rochester
$18,569,951
Attributed
$21,182,270
Total exposure
14
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2008–25$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$21,182,270 · 14
By mechanism
R01$21,182,270 · 14
Top collaborators
- Liewei Wang6 shared
- Robert W Mutter3 shared
- Josep Maria Domingo-Domenech2 shared
- Scott H Kaufmann2 shared
Most similar at Mayo Clinic Rochester
Same institution · by research overlap
- Eduardo N Chini$9,940,387
- Josep Maria Domingo-Domenech$5,429,135
- Veronica Rodriguez-Bravo$4,467,659
- Liewei Wang$11,536,599
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsResponsePathway InteractionsRegulationCellsDna DamageTumorigenesisProteinsCancer TherapyAffectTumorMutationInsightBaseLinkDesignDna RepairBrca1 GeneCancer CellGenome StabilityPhosphorylationOverexpressionMalignant Breast NeoplasmKnockout Mice
Grant awards (60)
Ovcoming PARP Inhibitor Resistance$633,705
R01 · FY2025 · CA · contact PI
Mechanism and therapeutic targeting of castration resistance in SPOP-mutated prostate cancer$492,046
R01 · FY2025 · CA · contact PI
ATR: targeting mechanical stress induced EMT and immune suppression in triple negative breast cancer$369,203
R01 · FY2025 · CA
Sensitizing Ovarian Cancer To PARP inhibitor and platinum treatment$363,713
R01 · FY2025 · CA · contact PI
Mechanism and therapeutic targeting of castration resistance in SPOP-mutated prostate cancer$507,395
R01 · FY2024 · CA · contact PI
ATR: targeting mechanical stress induced EMT and immune suppression in triple negative breast cancer$350,743
R01 · FY2024 · CA
Sensitizing Ovarian Cancer To PARP inhibitor and platinum treatment$345,528
R01 · FY2024 · CA · contact PI
The role of nuclear PD-L1 in breast tumor cell division, progression and therapy response$345,528
R01 · FY2024 · CA
ATR: targeting mechanical stress induced EMT and immune suppression in triple negative breast cancer$369,203
R01 · FY2023 · CA
Regulation of Necroptosis and inflammation$356,438
R01 · FY2023 · CA · contact PI
Sensitizing Ovarian Cancer To PARP inhibitor and platinum treatment$356,438
R01 · FY2023 · CA · contact PI
The role of nuclear PD-L1 in breast tumor cell division, progression and therapy response$356,438
R01 · FY2023 · CA
Regulation of Necroptosis and inflammation$356,438
R01 · FY2022 · CA · contact PI
Sensitizing Ovarian Cancer To PARP inhibitor and platinum treatment$356,438
R01 · FY2022 · CA · contact PI
The role of nuclear PD-L1 in breast tumor cell division, progression and therapy response$356,438
R01 · FY2022 · CA
UFM1 signaling in DNA damage response and cancer therapy$356,438
R01 · FY2022 · CA · contact PI
Sensitizing Ovarian Cancer To PARP inhibitor and platinum treatment$363,713
R01 · FY2021 · CA · contact PI
The role of nuclear PD-L1 in breast tumor cell division, progression and therapy response$363,713
R01 · FY2021 · CA
Regulation of Necroptosis and inflammation$363,713
R01 · FY2021 · CA · contact PI
UFM1 signaling in DNA damage response and cancer therapy$363,713
R01 · FY2021 · CA · contact PI
Deubiquitinases in regulation of BRCA1 pathway$363,713
R01 · FY2020 · CA · contact PI
The role of nuclear PD-L1 in breast tumor cell division, progression and therapy response$363,713
R01 · FY2020 · CA
Regulation of homologous recombination and cancer cell response to chemoradiotherapy$363,713
R01 · FY2020 · CA · contact PI
Regulation of Necroptosis and inflammation$363,713
R01 · FY2020 · CA · contact PI
UFM1 signaling in DNA damage response and cancer therapy$363,713
R01 · FY2020 · CA · contact PI
Regulation of Necroptosis and inflammation$363,713
R01 · FY2019 · CA · contact PI
Deubiquitinases in regulation of BRCA1 pathway$352,801
R01 · FY2019 · CA · contact PI
UFM1 signaling in DNA damage response and cancer therapy$352,801
R01 · FY2019 · CA · contact PI
Regulation of homologous recombination and cancer cell response to chemoradiotherapy$352,801
R01 · FY2019 · CA · contact PI
UFM1 signaling in DNA damage response and cancer therapy$363,713
R01 · FY2018 · CA · contact PI
Regulation of homologous recombination and cancer cell response to chemoradiotherapy$363,713
R01 · FY2018 · CA · contact PI
Ubiquitination and the DNA Damage Response Pathway$357,750
R01 · FY2018 · CA · contact PI
The Role of WSB1 in Tumorigenesis$329,925
R01 · FY2018 · CA · contact PI
Regulation of homologous recombination and cancer cell response to chemoradiotherapy$363,713
R01 · FY2017 · CA · contact PI
Ubiquitination and the DNA Damage Response Pathway$357,750
R01 · FY2017 · CA · contact PI
The Role of WSB1 in Tumorigenesis$329,925
R01 · FY2017 · CA · contact PI
Regulation of homologous recombination and cancer cell response to chemoradiotherapy$363,713
R01 · FY2016 · CA · contact PI
Ubiquitination and the DNA Damage Response Pathway$357,750
R01 · FY2016 · CA · contact PI
The Role of WSB1 in Tumorigenesis$329,925
R01 · FY2016 · CA · contact PI
Ubiquitination and the DNA Damage Response Pathway$357,750
R01 · FY2015 · CA · contact PI
The Role of WSB1 in Tumorigenesis$329,925
R01 · FY2015 · CA · contact PI
Regultion of p53 Deubiquitination$327,228
R01 · FY2015 · CA · contact PI
Ubiquitination and the DNA Damage Response Pathway$357,750
R01 · FY2014 · CA · contact PI
The Role of WSB1 in Tumorigenesis$329,925
R01 · FY2014 · CA · contact PI
Regultion of p53 Deubiquitination$317,411
R01 · FY2014 · CA · contact PI
Regultion of p53 Deubiquitination$307,594
R01 · FY2013 · CA · contact PI
Regulation of SirT1 by Deleted in Breast Cancer 1 (DBC1)$285,879
R01 · FY2013 · CA · contact PI
Regultion of p53 Deubiquitination$327,228
R01 · FY2012 · CA · contact PI
Regulation of SirT1 by Deleted in Breast Cancer 1 (DBC1)$304,127
R01 · FY2012 · CA · contact PI
The Role of MDC1 in Genome Maintenance and Tumor Suppression$304,127
R01 · FY2012 · CA · contact PI
Regultion of p53 Deubiquitination$327,228
R01 · FY2011 · CA · contact PI
The Role of MMSET in DNA damage response and Chemoradioresistance$317,411
R01 · FY2011 · CA · contact PI
Regulation of SirT1 by Deleted in Breast Cancer 1 (DBC1)$304,127
R01 · FY2011 · CA · contact PI
The Role of MDC1 in Genome Maintenance and Tumor Suppression$304,127
R01 · FY2011 · CA · contact PI
The Role of MMSET in DNA damage response and Chemoradioresistance$327,228
R01 · FY2010 · CA · contact PI
The Role of MDC1 in Genome Maintenance and Tumor Suppression$313,533
R01 · FY2010 · CA · contact PI
Regulation of SirT1 by Deleted in Breast Cancer 1 (DBC1)$313,533
R01 · FY2010 · CA · contact PI
The Role of MDC1 in Genome Maintenance and Tumor Suppression$313,533
R01 · FY2009 · CA · contact PI
Regulation of SirT1 by Deleted in Breast Cancer 1 (DBC1)$313,533
R01 · FY2009 · CA · contact PI
The Role of MDC1 in Genome Maintenance and Tumor Suppression$313,533
R01 · FY2008 · CA · contact PI